Ekso Bionics Holdings, Inc. (EKSO): Price and Financial Metrics
GET POWR RATINGS... FREE!
EKSO POWR Grades
- EKSO scores best on the Growth dimension, with a Growth rank ahead of 95.44% of US stocks.
- The strongest trend for EKSO is in Momentum, which has been heading down over the past 31 weeks.
- EKSO ranks lowest in Stability; there it ranks in the 11th percentile.
EKSO Stock Summary
- Ekso Bionics Holdings Inc's market capitalization of $67,957,318 is ahead of merely 10.83% of US-listed equities.
- Over the past twelve months, EKSO has reported earnings growth of 116%, putting it ahead of 86.03% of US stocks in our set.
- Ekso Bionics Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -73.58%, greater than the shareholder yield of only 3.07% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Ekso Bionics Holdings Inc, a group of peers worth examining would be MTBC, RMED, XENT, APDN, and ASPN.
- EKSO's SEC filings can be seen here. And to visit Ekso Bionics Holdings Inc's official web site, go to www.eksobionics.com.
EKSO Stock Price Chart Interactive Chart >
EKSO Price/Volume Stats
|Current price||$5.76||52-week high||$14.98|
|Prev. close||$5.73||52-week low||$3.05|
|Day high||$5.85||Avg. volume||394,564|
|50-day MA||$5.65||Dividend yield||N/A|
|200-day MA||$6.07||Market Cap||72.89M|
Ekso Bionics Holdings, Inc. (EKSO) Company Bio
Founded in 2005 in Richmond, California, Ekso Bionics Holdings Inc employs approximately 92 people that design, develop, and sell wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company’s first product, HULC was developed for the military in partnership with Lockheed Martin, enhancing soldier capabilities to allow them to carry heavier loads over further distances. The EksoNR is currently the only FDA-cleared exoskeleton for treatment of ABI, helping physical therapists, physiatrists, and doctors to clinically rehabilitate patients. The company’s CEO is Jack Peurach, who served as Executive Vice President, Products for SunPower Corp before becoming Ekso’s Chief Executive Officer.
EKSO Latest News Stream
|Loading, please wait...|
EKSO Latest Social Stream
View Full EKSO Social Stream
Latest EKSO News From Around the Web
Below are the latest news stories about Ekso Bionics Holdings Inc that investors may wish to consider to help them evaluate EKSO as an investment opportunity.
AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021
Biomerica Inc (NASDAQ: BMRA) has announced that its new COVID-19 Antigen Rapid Test can now be performed with a simple, less invasive nasal swab. The test is highly portable, cost-effective, and provides results in 15 minutes versus lab-run PCR tests, taking up to three days for results. Price Action: BMRA shares closed 17.3% lower at $3.41 on Tuesday. 908 Devices Inc (NASDAQ: MASS) has announced updates to its MX908 handheld mass spec device, including an aerosol module to detect and identify aerosolized chemical threats. The new capabilities also include added targets that allow responders to recognize additional priority drug substances and activate a Bluetooth capability to export reports and device history to Android devices. Price Action: MASS shares closed 5.8% lower at $44.44 on...
Following Successful Pilot Program, EksoNR will be Available at Four of Kindred’s Long-Term Acute Care Hospitals in Florida RICHMOND, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced an expanded partnership with Kindred Healthcare, LLC ("Kindred") bringing EksoNR, the most clinically used robotic exoskeleton, to four of Kindred’s Long-Term Acute Care (“LTAC”) Hospitals in the U.S. The multi-unit order follows a successful pilot program of the EksoNR last year. EksoNR has become a standard of care within Kindred’s Inpatient Rehabilitation Hospitals by driving patient outcomes in neurorehabilitation through early mobility and gait training. In 20...
Ekso Bionics (EKSO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RICHMOND, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2021 after the close of trading on Thursday, April 29, 2021. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the event will be available in the “Investors” section of the Company’s website at www.eksobionics.com, or by clicking here. Investors interested in listening to the conference call may do so by dialing 877-407-3036 for domestic callers or 201-378-4919 for international callers. A replay of the call will b...
EKSO Price Returns
Continue Researching EKSOWant to do more research on Ekso Bionics Holdings Inc's stock and its price? Try the links below:
Ekso Bionics Holdings Inc (EKSO) Stock Price | Nasdaq
Ekso Bionics Holdings Inc (EKSO) Stock Quote, History and News - Yahoo Finance
Ekso Bionics Holdings Inc (EKSO) Stock Price and Basic Information | MarketWatch